Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: A meta-analysis of six trials

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 6, 2012, Pages 861-873

  Qiu, Man Tang ^a,b   Ding, Xiang Xiang ^a   Hu, Jing Wen ^a,b   Tian, Hong Ya ^a   Yin, Rong ^a,b   Xu, Lin ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

Author keywords

Fixed dose rate; Gemcitabine; Non small cell lung cancer; Toxicities

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; ROFECOXIB;

ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; COMPARATIVE STUDY; DATA BASE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG INFUSION; DRUG RESPONSE; FATIGUE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84871252027     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1974-z     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108
2. Alberti W (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311(7010):899-909
3. Cardenal F, López-Cabrerizo MP, Antón A et al (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide- cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17(1):12-18
4. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18(1):122-130
5. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G (2003) Three-arm randomized study of two cisplatin- based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21(21):3909-3917
6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92-98
7. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 18(2):317-323
8. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2):330-353
9. Ettinger DS, Bepler G, Bueno R et al (2006) Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(6):548-582
10. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1998) Comparison of the cellular pharmacokinetics and toxicity of 20,20- difluorodeoxycytidine and 1-D-arabinofuranosylcytosine. Cancer Res 48(14):4024-4031
11. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 20,20-difluorodeoxy-cytidine on DNA synthesis. Cancer Res 51(22):6110-6117
12. Huang P, Plunkett W (1995) Fludarabine and gemcitabineinduced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36(3):181-188
13. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W (1990) Pharmacologically directed design of the dose rate and schedule of 2,2-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50(21):6823-6826
14. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21(18):3402-3408
15. Ceribelli A, Gridelli C, De Marinis F, Fabi A, Gamucci T, Cortesi E, Barduagni M, Antimi M, Maione P, Migliorino MR, Giannarelli D, Cognetti F (2003) Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98(2):337-343
16. Cappuzzo F, Novello S, De Marinis F, Selvaggi G, Scagliotti GV, Barbieri F, Maur M, Papi M, Pasquini E, Bartolini S, Marini L, Crino (2006) A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 52(3):319-325
17. Soo RA, Wang LZ, Tham LS, Yong WP, Boyer M, Lim HL, Lee HS, Millward M, Liang S, Beale P, Lee SC, Goh BC (2006) A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17(7):1128-1133
18. Gridelli C, Gallo C, Ceribelli A et al (2007) Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine- COxib in NSCLC (GECO) study. Lancet Oncol 8(6): 500-512
19. Wang LR, Huang MZ, Zhang GB, Xu N, Wu XH (2007) Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 60(4): 601-607
20. Pereira JR, Fein L, Del Giglio A, Blajman CR, Richardet E, Schwartsmann G, Orlando M, Hall BJ, West TM, van Kooten M (2007) Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer. Lung Cancer 58(1):80-87
21. Wang LR, Liu J, Huang MZ, Xu N (2007) Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B 8(5): 307-313
22. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924-926
23. Xiong JP, Feng M, Qiu F, Xu J, Tao QS, Zhang L, Xiang XJ, Zhong LX, Yu F, Ma XT, Gong WY (2008) Phase II trial of lowdose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Lung Cancer 60(2):208-214
24. Lee GW, Kang MH, Kim HG, Kang JH, Kim SH, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim HJ, Lee JS (2009) Fixeddose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer. Cancer Chemother Pharmacol 64(2):385-390
25. Wang L, Wu X, Huang M, Cai J, Xu N, Liu J (2007) The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 60(2):211-218
26. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9(3):491-498
27. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W (1991) Saturation of 20,20-difluorodeoxycytidine 50-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27(4):258-262
28. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine accumulation. J Clin Oncol 19(15):3483-3489
29. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ (2009) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 27(33):5506-5512
30. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic Carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27(23):3778-3785
31. Locher C, Fabre-Guillevin E, Brunetti F, Auroux J, Delchier JC, Piedbois P, Zelek L (2008) Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. Crit Rev Oncol Hematol 68(2):178-182
32. Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V (2009) Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol 4(9):1148-1155
33. Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, Vrankar M (2012) A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 23(2):230-238
34. Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54(10):1046-1055
35. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543-3551